In March 2017, Capnia, Inc. acquired Essentialis, Inc. and in May 2017 changed its name to Soleno Therapeutics, Inc., which is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Soleno is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), into Phase II/III clinical development during 2017. At this time, Soleno will continue to market Capnia’s legacy medical devices, including the CoSense® End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns, Serenz® Nasal Relief, an over-the-counter nasal allergy relief wash, and the NeoForce portfolio of neonatal pulmonary resuscitation solutions.
Our core commitment is to provide safe and effective products that make a difference by providing innovative solutions for unmet medical needs. Products everyone should have access to and that deliver a true benefit. As motivated physicians, researchers, and innovative leaders, it is our goal to make a difference in the lives of people everywhere by continuously improving and evaluating our goals and objectives to further the advancement of healthcare.
